Tirzepatide no worse than Ozempic-like drug for reducing heart issues

Embargoed until: Publicly released: 2025-12-18 09:00

Australia; International; VIC

Story by Olivia Henry, Australian Science Media Centre. IMAGE CREDIT: Photo by Towfiqu barbhuiya on Unsplash

Weight loss drug tirzepatide, sometimes sold as Mounjaro, seems no worse at reducing heart and stroke issues than the Ozempic-like diabetes drug dulaglutide (Trulicity), according to Aussie and international researchers. The study, which was funded by drug company Eli Lilly, compared in two groups of over 6,500 type 2 diabetes patients with heart disease who received either tirzepatide or dulaglutide, both of which are GLP-1RA drugs. The team says tirzepatide was not better than dulaglutide when looking at death from cardiovascular issues, heart attack, or stroke, but did also not seem to be worse. They also add that while adverse effects appeared similar, they did note more gastrointestinal issues in the tirzepatide group.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page The URL will go live after the embargo lifts.

Journal/
conference: NEJM

Research:Paper

Organisation/s: Monash University

Funder: Funded by Eli Lilly; SURPASS-CVOT ClinicalTrials.gov number, NCT04255433.

Media Contact/s

Contact details are only visible to registered journalists.